stockrowProtagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.
- Revenue
- +3,749.2%
- EPS
- +549.1%
- Free cash flow
- +839.7%
Quarter to June 2026, against a year earlier
Follow PTGX
Alert me
Protagonist Therapeutics, Inc. (PTGX) Revenue
Protagonist Therapeutics, Inc.'s revenue for fiscal 2025 was $46.0M, down 89.4% from $434.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was $282.0M. Over the past ten years it has ranged from $231.0K (fiscal 2019) to $434.4M (fiscal 2024); the current reading is higher than 78% of that period. Protagonist Therapeutics, Inc. ranks 59th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $46.0M | (89.41%) |
| FY2024 | $434.4M | 624.06% |
| FY2023 | $60.0M | 125.73% |
| FY2022 | $26.6M | (2.84%) |
| FY2021 | $27.4M | (4.44%) |
| FY2020 | $28.6M | 12,293.07% |
| FY2019 | $231.0K | (99.25%) |
| FY2018 | $30.9M | 54.14% |
| FY2017 | $20.1M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $213.5M | 278.72% |
| Mar 2026 | $56.4M | 657.94% |
| Dec 2025 | $7.4M | 57.83% |
| Sep 2025 | $4.7M | (15.04%) |
| 26 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| MDGL Madrigal Pharmaceuticals, Inc. compare | $1.4B |
| CAI Caris Life Sciences,�Inc. compare | $1.0B |
| TGTX TG Therapeutics, Inc. compare | $799.5M |
| KRYS Krystal Biotech, Inc. compare | $470.0M |
| TWST Twist Bioscience Corporation compare | $431.8M |
| PTGX Protagonist Therapeutics, Inc. | $282.0M |
| IBRX ImmunityBio, Inc. compare | $165.8M |
| CYTK Cytokinetics, Incorporated compare | $113.3M |
| SYRE Spyre Therapeutics, Inc. compare | $1.1M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on PTGX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement